Compare · NVO vs ZYBT
NVO vs ZYBT
Side-by-side comparison of Novo Nordisk A/S (NVO) and Zhengye Biotechnology Holding Limited (ZYBT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZYBT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 4216.6x ZYBT ($43.6M).
- Over the past year, NVO is down 34.2% and ZYBT is down 92.6% - NVO leads by 58.4 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 3 for ZYBT).
- NVO has more recent analyst coverage (25 ratings vs 0 for ZYBT).
- Company
- Novo Nordisk A/S
- Zhengye Biotechnology Holding Limited
- Price
- $41.18+6.93%
- $1.03+8.80%
- Market cap
- $183.82B
- $43.6M
- 1M return
- +13.32%
- +24.10%
- 1Y return
- -34.24%
- -92.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest ZYBT
- SEC Form 3 filed by new insider Hu Qiyi
- SEC Form 3 filed by new insider Li Guohan (Nmn)
- Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure
- SEC Form 3 filed by new insider Lian Wei
- SEC Form 3 filed by new insider Liu Zhongyao
- SEC Form 3 filed by new insider Sun Wenhua
- SEC Form 3 filed by new insider Han Aiden
- SEC Form 6-K filed by Zhengye Biotechnology Holding Limited
- Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders
- SEC Form 6-K filed by Zhengye Biotechnology Holding Limited